Comparison between two biodegradable polymer-based sirolimus-eluting stents with differing drug elution and polymer absorption kinetics: two-year clinical outcomes of the PANDA III trial
EuroIntervention 2018;14:e1029-e1037 published online February 2018 published online e-edition October 2018. DOI: 10.4244/EIJ-D-17-00946
Juan Wang1, MD; Changdong Guan1, MSc; Shubin Qiao1*, MD; Xuebin Cao2, MD; Lei Qin3, MD; Yi Li4, MD; Zhanquan Li5, MD; Xueqi Li6, MD; Jiansong Yuan1, MD; Runlin Gao1, MD; Bo Xu1, MBBS; on behalf of the PANDA III Investigators
1. Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; 2. Chinese PLA 252 Hospital, Baoding, China; 3. Kaifeng Central Hospital, Kaifeng, China; 4. Yunnan St. John’s Hospital, Kunming, China;
Aims: In the PANDA III trial, the novel poly-lactide-co-glycolide polymer-based BuMA sirolimus-eluting stent (SES) was non-inferior to the polylactide polymer-based Excel SES for the prim
